Global law firm Norton Rose Fulbright has advised Jacobson Pharma Corporation Limited (Jacobson Pharma) on the spin-off listing of its branded healthcare business on the Main Board of the Stock Exchange of Hong Kong.
Based in Hong Kong, Jacobson Pharma is a market leader in the pharmaceutical industry in the research, development, production, marketing and sale of essential medicines and branded healthcare products. The spin-off group, JBM (Healthcare) Limited (JBM), also Hong Kong-based, is a branded healthcare company with a product footprint across Greater China, Southeast Asia and other select countries. JBM specialises in the manufacturing and trading of branded healthcare products, comprising consumer healthcare products and proprietary Chinese medicines.
Psyche Tai, head of Hong Kong and partner who led on the deal, commented:
“The spin-off will create growth opportunities and increase value for JBM. The market remains active and our team continues to advise on a number of IPOs in the region.”
The Hong Kong based team also included partner Harold Tin, counsel Rachel Chan and associates Patrick Wong, Ying Yeo and Zoe Tang.